Cargando…

An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers

BACKGROUND: The reason for the poor prognosis of estrogen receptor (ER) + /human epidermal growth factor receptor 2 (HER2)− breast cancer patients with high levels of tumor-infiltrating lymphocytes (TILs) is poorly understood. The association between TILs and response to neoadjuvant endocrine therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukui, Reiko, Watanabe, Takahiro, Morimoto, Koji, Fujimoto, Yukie, Nagahashi, Masayuki, Ishikawa, Eri, Hirota, Seiichi, Miyoshi, Yasuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404203/ https://www.ncbi.nlm.nih.gov/pubmed/37115435 http://dx.doi.org/10.1007/s12282-023-01462-5

Ejemplares similares

Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine
por: Imamura, Michiko, et al.
Publicado: (2019)

Significant association between high serum CCL5 levels and better disease‐free survival of patients with early breast cancer
por: Fujimoto, Yukie, et al.
Publicado: (2019)

Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With Cell Proliferation and Better Survival But Not Always With Chemotherapy Response in Breast Cancer
por: Wu, Rongrong, et al.
Publicado: (2023)

Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in (18)F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy
por: Higuchi, Tomoko, et al.
Publicado: (2019)

The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
por: Long, Mengping, et al.
Publicado: (2022)

Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin
por: Bun, Ayako, et al.
Publicado: (2023)

Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of (18)F-deoxyglucose levels on positron emission tomography for breast cancers
por: Nishimukai, Arisa, et al.
Publicado: (2017)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

A case of planar-type GIST of the sigmoid colon showing diverticular structure with perforation
por: Shintaku, Yuka, et al.
Publicado: (2020)

Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer
por: Brodsky, Alexander S., et al.
Publicado: (2016)

Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes
por: Liu, Shiwei, et al.
Publicado: (2020)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy
por: Chaudhary, Lubna Naaz, et al.
Publicado: (2023)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2018)

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
por: Chen, Hai-long, et al.
Publicado: (2023)

Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes
por: Lizcano, Fernando
Publicado: (2022)

Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2015)

Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer
por: Hagio, Kanako, et al.
Publicado: (2021)

ENDOCRINE DISRUPTORS: Estrogens in a Bottle?
por: Barrett, Julia R.
Publicado: (2009)

Editorial: Estrogen receptors in endocrine disorders
por: Filardi, Tiziana, et al.
Publicado: (2023)

Predictors of lymphovascular invasion in estrogen receptor positive/Her-2 negative breast cancer patients treated with neoadjuvant chemotherapy
por: ÇAVDAR, Eyyüp, et al.
Publicado: (2022)

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
por: Kim, Hee Jeong, et al.
Publicado: (2020)

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial
por: Issa-Nummer, Yasmin, et al.
Publicado: (2013)

Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
por: Liu, Xi-Yu, et al.
Publicado: (2018)

Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer
por: Ragusi, Max AA, et al.
Publicado: (2021)

The Endocrine Role of Estrogens on Human Male Skeleton
por: Rochira, Vincenzo, et al.
Publicado: (2015)

Non-canonical Estrogen Signaling in Endocrine Resistance
por: Ranganathan, Prathibha, et al.
Publicado: (2019)

Biomarker Genes for Detecting Estrogenic Activity of Endocrine Disruptors via Estrogen Receptors
por: Jung, Eui-Man, et al.
Publicado: (2012)

Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells
por: Thaler, Sonja, et al.
Publicado: (2017)

Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women—a literature review and proposed guidelines
por: Madigan, Lauren I., et al.
Publicado: (2020)

Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial
por: Yokomizo, Akira, et al.
Publicado: (2021)

The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer
por: Isnaldi, Edoardo, et al.
Publicado: (2022)

Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer
por: Madeira, Marcelo, et al.
Publicado: (2013)

Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
por: Yang, Xia, et al.
Publicado: (2018)

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
por: Mizuno, Takaaki, et al.
Publicado: (2020)

Problems for risk assessment of endocrine-active estrogenic compounds.
por: Safe, Stephen H, et al.
Publicado: (2002)

Estrogen receptor degradation: a CUE for endocrine resistance?
por: Musgrove, Elizabeth A
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_onudg00dm3smm8k00ol36rihc9